Our Company has constructed a full human naive antibody library of 10^11 scale. Leveraging phage display technology, our in vitro screening system on the platform reduces the reliance on animal immune systems to produce antibodies. The screening technology allows us to significantly shorten the development period of innovative drug candidates to four to six weeks, compared to the traditional hybridoma technology which generally takes four to six months. Our Company has also constructed a trispecific antibody T cell engager platform by utilizing protein binding domains, such as nanobodies and scFv, to augment T cells’ response to solid tumors.